AKRO News and Press, Akero Therapeutics Inc. From 02/23/21

Akero Therapeutics to Participate in Upcoming Virtual Healthcare Conferences in March PR Newswire SAN FRANCISCO , Feb. 23, 2021 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformat...

Hepion's leading candidate CRV431 may have the best anti-fibrotic effect among the numerous NASH candidates. CRV431's analogs have been widely studied in various clinical trials, and were proven to be well-tolerated. Hepion's management has extensive experience with cyclophilin in...

Gainers: [[RDHL]] +25.6%. [[GOGO]] +18.6%. [[BBBY]] +17.3%. [[RYTM]] +14.6%. [[AKRO]] +13.6%.Losers: [[OPCH]] -16.7%. [[GRTX]] -16.6%. [[TTOO]] -15.3%. [[WMG]] -7.7%. [[FFIV]] -7.5%. For further details see: BBBY, RDHL, TTOO and OPCH among after-hours movers

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today announced that management will present virtually at the 39 th An...

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today announced that management will participate in a fireside chat at Eve...

Data to be presented at the Presidential Plenary Talk at The Liver Meeting® 100% of patients in 50mg group demonstrated more than 50% relative reduction in liver fat 50% of patients with F2/F3 fibrosis at baseline achieved two stage improvement in fibrosis score ...

Akero Therapeutics (AKRO): Q3 GAAP EPS of -$0.63 beats by $0.03.Cash, cash equivalents and short-term marketable securities of $291.9M.Press Release For further details see: Akero Therapeutics EPS beats by $0.03

Akero Therapeutics Reports Third Quarter 2020 Financial Results PR Newswire SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-a...

Akero Therapeutics To Present At Upcoming Conferences In November PR Newswire SOUTH SAN FRANCISCO, Calif., Oct. 21, 2020 SOUTH SAN FRANCISCO, Calif., Oct. 21, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnol...

The European Medicines Agency ((EMA)) has granted Priority Medicines ((PRIME)) designation to Akero Therapeutics' (AKRO) efruxifermin ((EFX)), an investigational FGF21 analog for the treatment of non-alcoholic steatohepatitis ((NASH)).PRIME, akin to Breakthrough Therapy status in the U.S., pr...